Skip to main content
. 2021 Jan 15;10:607840. doi: 10.3389/fonc.2020.607840

Table 3.

EGFR and KRAS co-mutated cases.

Patients ID Diagnosis -Sensitizing MUT EGFR Progression Disease -  MUT EGFR in liquid biopsy KRAS n° of positive droplets (MAFA) Age at diagnosis (years) Smoking PS Stage at Diagnosis PFS (months) TTF (months) OS (months)
88 L858R no mutation 4 (0.11%) 77 yes 1 IV 2 4 4
13 ex19 del ex19 del 3 (0.11%) 65 ex 1 IV 5 6 18
39 ex19 del ex19del-T790M 3 (0.036%) 71 yes 0 IV 5 5 6